التفاصيل البيبلوغرافية
| العنوان: |
Data from F. Hoffmann-La Roche - Roche Pharma Research and Early Development Broaden Understanding of Cancer (Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy). |
| المصدر: |
Immunotherapy Weekly; 12/14/2023, p158-158, 1p |
| مصطلحات موضوعية: |
IMMUNOTHERAPY, RESEARCH & development, CYTOKINES, RESEARCH personnel, INTERLEUKIN-4 |
| مصطلحات جغرافية: |
GERMANY |
| مستخلص: |
A recent report from F. Hoffmann-La Roche - Roche Pharma Research and Early Development in Penzberg, Germany, discusses the development of targeted cytokines for cancer immunotherapy. The researchers engineered a platform for targeted conditionally active type I cytokines by splitting the type I cytokine interleukin-4 (IL-4) into two inactive IL-4 prodrugs and fusing them to antibody-like molecules. This approach allows for the preferential reconstitution of active IL-4 on target cells, reducing systemic toxicity and increasing tumor penetration. The study demonstrates the effectiveness of targeted on-cell prodrug conversion and suggests that this approach could be expanded to develop other targeted conditionally active cytokines for cancer immunotherapy. [Extracted from the article] |
|
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
